Bardin Hill Management Partners’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Bardin Hill Management Partners’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-6,837	Closed	-$900K	–	109
2020 Q4	$900K	Buy	+6,837	New	+$604K	0.19%	34

Bardin Hill Management Partners's EIDX Position: Q1 2021 in Review

Bardin Hill Management Partners sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 6,837 shares — an estimated $900K sold.

Bardin Hill Management Partners first reported a position in EIDX in Q4 2020 and held it in 1 quarter. The position peaked at $900K in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Bardin Hill Management Partners reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Bardin Hill Management Partners sold 6,837 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $900K.
Bardin Hill Management Partners first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Bardin Hill Management Partners's Eidos Therapeutics, Inc. Common Stock position peaked at $900K in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Bardin Hill Management Partners's 13F filing for Q1 2021, filed 14 May 2021.